Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VACCINEX, INC.VCNX · Entity 9673 | Director | May 15, 2019 | May 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VACCINEX, INC.
Report date May 15, 2019 · Filed May 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 | Direct | 7,718 |
Reported balance
After 2019-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-15 · Grant · Acquired 7,718 · Balance 7,718 F2: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2027-09-15 | Direct | 6,396 |
Reported balance
Holding disclosure · report date 2019-05-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 6,396 F1: Exercisable in full as of the date of this report. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable in full as of the date of this report.
F2: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2019 Filed May 17, 2019 16:42 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 7,718 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0000891839-19-000071 · edgar.xml · derivative · entry 2 Berlin Alejandro M. · CIK 0001747958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,718 Underlying: Common Stock · 7,718 shares Expires not disclosed F2 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.